Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.

NCT06047379 is registered in ClinicalTrials.gov with Neonc Technologies, Inc. as lead sponsor.

NCT NCT06047379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06047379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.
Lead sponsor
Neonc Technologies, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 1, 2023
Completion date
August 31, 2027
Enrollment
134 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, adult, cervical cancer, colorectal cancer, diffuse astrocytoma, idh-mutant, esophageal cancer, esophageal squamous cell carcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, glioblastoma, idh-wildtype, head and neck squamous cell carcinoma, melanoma, merkel cell carcinoma, microsatellite instability-high colorectal cancer, microsatellite instability-high solid malignant tumor, mismatch repair deficient colorectal cancer, mismatch repair deficient solid malignant tumor, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, squamous cell carcinoma, urothelial carcinoma